6.6.4. combination therapies. following combination therapies studied continuous adt, intermittent adt. 6.6.4.1.‘combined’ androgen blockade older generation nsaa (bicalutamide, flutamide, nilutamide) systematic reviews shown cab using nsaa appears provide small survival advantage (< 5%) vs. monotherapy (surgical castration lhrh agonists) minimal survival advantage must balanced increased side effects. addition, newer combination therapies (see tables 6.4.3, 6.4.4, 6.4.5) effective shown specifically enzalutamide tested nsaa phase iii trial . recently another trial demonstrated significant os benefit addition rezvilutamide vs. addition bicalutamide adt patients high-volume mhspc . therefore combination nsaas considered combination therapies available. 6.6.4.2. androgen deprivation combined agents 6.6.4.2.1. androgen deprivation therapy combined chemotherapy three large rcts conducted . trials compared adt alone soc adt combined immediate docetaxel (75 mg/sqm, every three weeks within three months adt initiation). primary objective three studies assess os. key findings summarised table 6.4.3. table 6.6.3: key findings - hormonal treatment combined chemotherapy stampede getug-afu 15 chaarted adtadt + docetaxel(6 cycles) + padtadt + docetaxel(9 cycles)adtadt + docetaxel(6 cycles)n1,184592193192393397newly diagnosed m+58%59%75%67%73%73%key inclusion criteriapatients scheduled long-term adt- newly diagnosed m1 n+ situations- locally advanced (at least two ct3 ct4, isup grade > 4, psa > 40 ng/ml)- relapsing locally treated disease psa > 4 ng/ml psa-dt < 6 mo.or psa > 20 ng/ml,or nodalor metastatic relapsemetastatic disease karnofsky score > 70%metastatic diseaseecog ps 0, 1 2primary objectiveosososmedian follow (mo)43; 78.2 (update m1)5054 (update)hr (95% ci)0.78 (0.66-0.93)1.01 (0.75-1.36)0.72 (0.59-0.89)m1 onlyn1,086--hr (95% ci)0.81 (0.69-0.95)-- adt = androgen deprivation therapy; ci = confidence interval; ecog = eastern cooperative oncology group; hr = hazard ratio; isup = international society urological pathology; mo = month; n = number patients; os = overall survival; p = prednisone; psa-dt = prostate-specific antigen-doubling time. getug 15 trial, patients m1 pca, either de novo primary treatment . stratified based previous treatment glass risk factors . chaarted trial inclusion criteria applied, patients stratified according disease volume (see table 6.4.1) . stampede multi-arm multi-stage trial reference arm (adt monotherapy) included 1,184 patients. one experimental arms docetaxel combined adt (n = 593), another docetaxel combined zoledronic acid (n = 593). patients included either m1 n1 two following three criteria: t3/4, psa ≥ 40 ng/ml isup grade group 4–5. also relapsed patients local treatment included met one following criteria: psa ≥ 4 ng/ml psa-dt < six months psa ≥ 20 ng/ml, n1 m1. stratification used regarding metastatic disease volume (high/low volume) . three trials toxicity mainly haematological around 12–15% grade 3–4 neutropenia, 6–12% grade 3–4 febrile neutropenia. use granulocyte colony-stimulating factor receptor (gcsf) shown beneficial reducing febrile neutropenia. primary secondary prophylaxis gcsf based available guidelines . docetaxel three trials used standard dose 75 mg/sqm every three weeks, six cycles chaarted stampede nine cycles getug-afu-15. subgroup analyses getug-afu 15 chaarted beneficial effect addition docetaxel adt evident men de novo metastatic high-volume disease , range whatever volume post-hoc analysis stampede . effect adding docetaxel less apparent men prior local radical treatment although numbers small event rates lower. sr meta-analysis included three trials showed addition docetaxel soc improved survival . hr 0.77 (95% ci: 0.68–0.87, p < 0.0001) translates absolute improvement 4-year survival 9% (95% ci: 5–14). sr meta-analysis individual participant data three trials shown meaningful beneficial effect addition docetaxel adt patients metachronous low volume disease. interestingly largest absolute improvement five years observed patients high volume clinical stage four disease . based data, upfront docetaxel combined adt considered standard men presenting metastases first presentation, provided fit enough receive docetaxel . recently two large phase iii studies shown os benefit adding arpi adt docetaxel. therefore adding docetaxel alone adt considered arpi available available ones contraindicated (see section 6.4.4.2.3). 6.6.4.2.2. combination arpi alone (abiraterone, apalutamide, enzalutamide) two large rcts (stampede, latitude) addition abiraterone acetate (1000 mg daily) plus prednisone (5 mg daily) adt men mhspc studied (see table 6.4.4). primary objective trials improvement os. trials showed significant os benefit. latitude de novo high-risk metastatic patients included, hr reached 0.62 (0.51–0.76) . hr stampede similar 0.63 (0.52–0.76) total patient population (metastatic non-metastatic) hr 0.61 subgroup metastatic patients . high-risk patients included latitude trial post-hoc analysis stampede showed benefit whatever risk volume category . secondary objectives pfs, time radiographic progression, time pain, time chemotherapy favour combination. difference treatment-related deaths observed combination adt plus aap compared adt monotherapy (hr: 1.37 [0.82–2.29]). however, twice many patients discontinued treatment due toxicity combination arms stampede (20%) compared latitude (12%) . based data upfront aap combined adt considered standard men presenting metastases first presentation, provided fit enough receive drug. three large rcts (titan, arches enzamet) addition ar antagonists adt men mhspc tested . arches primary endpoint radiographic pfs (rpfs). primary analysis rpfs significantly improved combination enzalutamide adt hr 0.39 (0.3–0.5). approximately 36% patients low-volume disease; around 25% prior local therapy 18% patients received prior docetaxel. final prespecified analysis key secondary enpoint os significantly improved hr 0.66 (0.53-0.81) significant benefit rpfs maintained hr 0.63 (0,52–0.76) . enzamet primary endpoint os. addition enzalutamide adt first analysis improved os hr 0.67 (0.52–0.86) compared adt plus non-steroidal antiandrogen. approximately half patients concomitant docetaxel; 40% prior local therapy half patients low-volume disease . planned later analysis median follow-up 68 months os benefit adding enzalutamide maintained hr 0.7 (0.58-0.84) titan trial, adt plus apalutamide used rpfs os co-primary endpoints. primary analysis rpfs significantly improved addition apalutamide hr 0.48 (0.39–0.6); os 24 months improved combination hr 0.67 (0.51–0.89). final analysis hr os 0.65 (0.53–0.79) without adjustment cross-over. trial 16% patients prior local therapy, 37% low-volume disease 11% received prior docetaxel . recently published chart trial, adt plus rezvilutamide tested vs. adt plus bicalutamide patients high-volume de novo metastatic disease. ninety percent patients recruited china. overall survival rpfs co-primary endpoints. pre-planned interim analysis rezvilutamide significantly improved rpfs compared bicalutamide hr 0.44 (0.33–0.58) os hr 0.58 (0.44–0.77) . summary, addition new ar antagonists significantly improves clinical outcomes convincing evidence differences subgroups. majority patients de novo metastatic disease evidence compelling situation. trials new ar antagonists, proportion patients metachronous disease (see table 6.4.5); subgroup analyses effect seemed consistent therefore, combination also offered men progressing radical local therapy . table 6.6.4: results stampede arm g latitude studies stampede latitude adtadt + aa + padt + placeboadt + aa + pn957960597602newly diagnosed n+20%19%00newly diagnosed m+50%48%100%100%key inclusion criteriapatients scheduled long-term adt- newly diagnosed m1 n+ situations- locally advanced (at least two ct3 ct4, isup grade > 4, psa > 40 ng/ml)- relapsing locally treated disease psa > 4 ng/ml psa-dt < 6 mo.or psa > 20 ng/mlor nodalor metastatic relapsenewly diagnosed m1 disease 2 3 risk factors: isup grade > 4, > 3 bone lesions, measurable visceral metastasisprimary objectiveososradiographic pfsmedian follow (mo)4030.43-yr. os83% (adt + aa + p)76% (adt)66% (adt + aa + p)49% (adt + placebo)hr (95% ci)0.63 (0.52-0.76)0.62 (0.51-0.76)m1 onlyn1,0021,1993-yr. osna66% (adt + aa + p)49% (adt + placebo)hr (95% ci)0.61 (0.49-0.75)0.62 (0.51-0.76)hrffs (biological, radiological, clinical death): 0.29 (0.25-0.34)rpfs:0.49 (0.39-0.53) aa = abiraterone acetate; adt = androgen deprivation therapy; ci = confidence interval; ffs = failure-freesurvival; hr = hazard ratio; isup = international society urological pathology; mo = month; n = number patients; na = available; os = overall survival; p = prednisone; rpfs = radiographic progression-free survival; psa = prostate-specific antigen; yr. = year. table 6.6.5: results enzamet titan studies os primary endpoint enzamet titan adt+ older antagonist± docetaxel (soc)adt + enzalutamide ± docetaxeladt + placeboadt + apalutamiden562563527525newly diagnosed m+72.1%72.5%83.7%78.3%low volume47%48%36%38%primary objectiveososrpfsmedian follow (mo)3430.43-yr. os3-yr survival:80% (adt + enzalutamide)72% (soc)2-yr survival:84% (adt + apalutamide)74% (adt + placebo)hr (95% ci) os0.67 (0.52-0.86)0.67 (0.51-0.89) adt = androgen deprivation therapy; ci = confidence interval; hr = hazard ratio; mo = month; n = number ofpatients; os = overall survival; soc = standard care; rpfs = radiographic progression-free survival; yr = year. table 6.6.6: results arches chart studies arches chart adt ± docetaxeladt + enzalutamide ± docetaxeladt +bicalutamideadt + rezvilutamiden576574328326newly diagnosed m+63%70%100%100%low volume35%38%0%0%use early docetaxel18% (previous)18% (previous)0%0%primary objectiverpfsosrpfsmedian follow (mo)44.629.3median rpfs (mo.)38.949.823.5not reachedhr (95% ci) rpfshr: 0.63 (0.52–0.76)hr: 0.46 (0.36–0.60)median osnot reachednot reachednot reachednot reachedhr (95% ci) os0.66 (0.53–0.81): main secondary endpoint0.58 (0.44–0.77) hr = hazard ratio; mo = month; n = number patients; os = overall survival; rpfs = radiographic progression-free survival; yr = year. 6.6.4.2.3. combination docetaxel arpi addition abiraterone adt docetaxel reported benefit rpfs os peace-1 trial . trial 2x2 factorial design participants de novo (synchronous) metastatic pca randomised soc; beginning trial adt, later adt plus docetaxel 6 cycles chemotherapy-fit) vs. soc plus radiotherapy vs. soc plus abiraterone vs. soc plus radiotherapy plus abiraterone. co-primary endpoints rpfs os, statistically significantly improved total population. also group patients received adt plus docetaxel soc (n = 710) rpfs os increased hr: 0.5 (0.34–0.71) 0.75 (0.59–0.95), respectively. note; population 35% low-volume disease. toxicity modestly increased, mostly hypertension. arasens phase iii trial patients received adt docetaxel 6 cycles soc plus darolutamide placebo . 1,306 metastatic patients included, 14 % relapsed disease radical local treatment (metachronous). primary endpoint os statistically significanty increased addition darolutamide hr 0.68 (0.57–0.8). interestingly, trial occurrence aes similar arms. trials docetaxel arpi given concomitantly. included patients 77% high volume 70% high-risk disease. unplanned subgroup analysis beneficial effect adding darolutamide versus placebo os seen patients high-volume (hr 0.69; 0.57-0.82), high-risk (hr 0.71; 0.58-0.86) low-risk disease (hr 0.62; 0.42-0.9), small subgroup patients low-volume disease results suggestive os benefit (hr 0.68; 0.41-1.13) also enzamet, titan arches patients received docetaxel part soc, thus concomitantly, percentage patients receiving docetaxel trials much lower . also srs network meta-analysis systemic triplet therapies confirm triplets effective adt docetaxel alone , one analysis looking subgroups statistically significant patients high volume disease de novo disease .